BURKHOLDERIA CEPACIA COMPLEX

Taxonomy
Pseudomonas (Burkholderia) cepacia was originally described by Walter H. Burkholder as the causative agent of 'sour skin' onion rot. Due to its phenotypic characteristics including utilization of various carbon sources and the presence of polar flagella, this bacterium was originally placed in the genus Pseudomonas. The species name cepacia was given because of the association of this bacterium with onions, caepa being the genus name for onions. 1 Based on biochemical, phenotypic, and genetic characteristics, in 1992 the RNA homology group II of the genus Pseudomonas was given a new genus name. Yabuuchi et al. 2 proposed that seven species, including Pseudomonas cepacia, be given the genus name Burkholderia in honor of the bacteriologist who characterized Burkholderia (Pseudomonas) cepacia.
As more isolates were characterized and designated B. cepacia, distinct genetic differences were found between various strains. These phenotypically similar bacteria were grouped into a B. cepacia complex (Bcc) and subsequently separated into genomovars based upon genetic variances. 3 When a genomovar can be distinguished by a phenotypic characteristic it is given a species name. 4 For example, Bcc genomovar V strains have the distinct ability to fix nitrogen and were given the name B. vietnamiensis. 5 Currently, there are nine different genomovars, with seven having species names. There will likely be additional genomovars and species as more isolates are characterized and phenotypes distinguished ( Table 1) .
Taxonomy of Bcc has had a complex history, but for the most part, the phenotypic analyses for identification of Bcc have remained the same. For this review, the authors have made the assumption that bacterial strains previously identified in the literature as Pseudomonas cepacia or Burkholderia cepacia would now be included in the B. cepacia complex. As many of the bacterial isolates have since been re-characterized and deemed to be a part of the Bcc, this assumption has credence. A more complete description of the taxonomy of Bcc has been recently published by Coenye et al. 10 
Utility of Bcc in the environment
Bcc is naturally found in water, soil, and associated with the rhizosphere of plants; thus, this organism can potentially have some environmental impacts. Not only can Bcc cause plant diseases like 'sour skin' onion rot, 1 but it can also prevent some plant diseases including 'damping-off ' disease of seeds caused by Pythium spp. and Rhizoctonia solani, [11] [12] [13] and root rot by Aphanomyces euteiches. 14 Bcc also inhibits growth of gray mold and blue mold on fruit. 15 These effects are due to the production of several antimicrobial compounds by Bcc making it as effective as a chemical fungicide. 12, [15] [16] [17] Some Bcc strains can also increase plant growth and crop production due to their ability to colonize plant roots and fix nitrogen using a nitrogenase. 18 These characteristics make Bcc an attractive option for agricultural use over synthetic chemicals.
Bcc strains are able to utilize many different carbon compounds as energy sources. 16 One Bcc strain was able to completely degrade trichloroethylene, a common contaminant of groundwater with possible toxic and carcinogenic effects. 19 The synthetic herbicides 2,4,5-trichlorophenoxyacetic acid (2,4,5-T) and 2,4-dichlorophenoxyacetate (2,4-D) were shown to be degraded by another Bcc strain that was selected for these properties. [20] [21] [22] These studies indicate that Bcc has the potential to be developed and used as a bioremediation agent. More detailed information on the role of Bcc in the environment has been recently reviewed by Parke et al. 23 
Bcc in human infections
By 1970, occasional descriptions of Bcc infecting immunocompromised patients in hospitals were being discussed in the medical literature. 24, 25 Most patients suffered from either respiratory infections or infections derived from contaminated hospital equipment -for example, catheters contaminated with Bcc caused an outbreak of urinary tract infections in the early 1970s. 24 It was noticed in the 1980s that several chronic granulomatous disease (CGD) patients had respiratory tract infections with Bcc. 26 Individuals with CGD have a genetic defect making them unable to produce superoxide and its derivatives rendering them more susceptible to bacterial and fungal infections. 27, 28 It was also demonstrated that leukocytes isolated from CGD patients were unable to kill Bcc. 29 Currently, Bcc infection is reported to be the second leading cause of death in CGD patients. 28 Bcc infections have also been found in healthy individuals. Bcc is consistently isolated from the feet of otherwise healthy individuals with 'swamp rot' or 'foot rot', a condition commonly observed after military persons have undergone swamp training, where their feet are continuously exposed to contaminated water. 30 In the 1970s, Bcc began to be isolated from the lungs of cystic fibrosis (CF) patients. 31 CF, a genetic disease which affects approximately 1 in 2500 Caucasians, is caused by a mutation in the CF transmembrane conductance regulator, a chloride ion channel. This mutation affects the body's mucous membranes resulting in, among other conditions, the accumulation of thick mucous in the lungs making it more difficult to clear infections. Thus, bacterial infections of the lungs are common, including the Gram-negative bacterium P. aeruginosa, and are the main cause of morbidity and mortality of these patients <http://www.cff.org>. 32 Currently, about 3.5% of all CF patients are infected with Bcc, with infection rates of up to 40% in some CF treatment centers <http://www.cff.org>. 33, 34 The majority of CF patients with Bcc infection are either asymptomatic or have a slow, progressive deterioration in lung function. However, about 20% of infected patients develop 'cepacia syndrome', which is characterized by a rapid decline in respiratory capacity, bacteremia, septicemia, and eventually death. 31, 35 Infections by Bcc and P. aeruginosa in CF patients has been reviewed by Govan and Deretic. 36 There are two possible reasons for the increased incidence of Bcc infection in CF patients over the past three decades. First is the increased use of antibiotics to which Bcc is resistant. 37, 38 Some Bcc isolates can express an active antibiotic efflux protein and/or a highly active b-lactamase. [38] [39] [40] Bcc also has an outer membrane that is impermeable to many antibiotics. 41 A second possible explanation is that, unlike P. aeruginosa, some strains of the Bcc can be transmitted between individuals causing epidemics within the CF community. [42] [43] [44] One such highly 202 Vinion-Dubiel, Goldberg transmissible Bcc genomovar III strain is called ET12, as isolates of this strain have been found in CF patients from Edinburgh, Scotland and Toronto, Canada. 45 The genome of an isolate from the Bcc ET12 lineage, J2315, is currently being sequenced by the Sanger Institute <http://www.sanger.ac.uk/Projects/B_cepacia/>. Due to the potential utility of Bcc in the environment and its unfortunate ability to cause infections in humans, studies have focused on identifying potential virulence factors. A majority of Bcc strains isolated from the lungs of CF patients, particularly CF epidemic strains like ET12, are genomovar III or B. multivorans (genomovar II). 3 However, all Bcc genomovars have been found in the lungs of CF patients. Likewise, all Bcc genomovars, including genomovar III, have been isolated from the environment. 46, 47 Potential Bcc virulence factors include the cable pilus and a chromosomal marker designated the B. cepacia epidemic strain marker. 45, 48, 49 However, these factors, like the genomovar, are not fully indicative of the capacity of a Bcc strain to cause human infection. 50, 51 
ROLE OF LIPOPOLYSACCHARIDE IN Bcc INFECTION
Lipopolysaccharide toxicity
As lipopolysaccharide (LPS) is a virulence factor of many Gram-negative bacteria, the LPS of Bcc has been well studied. Whole Bcc bacteria are not toxic to outbred mice or guinea pigs, unless the animals are injected with large doses. 52, 53 However, an extracellular toxic complex (ETC) made from supernatants of liquid Bcc cultures was lethal when injected into mice. Furthermore, ETC induced pulmonary pathology in rats, even in the absence of an active Bcc infection. 54 Later studies by the same group demonstrated that the toxic component of ETC was LPS. 54, 55 As demonstrated using a Limulus amoebocyte lysate assay, Bcc LPS can induce endotoxic activity to a similar level as that induced by Escherichia coli LPS. This is about 4-5 times more endotoxic than LPS isolated from the common CF pathogen P. aeruginosa. 56 This high toxicity was exhibited regardless of the source of the Bcc strain, whether clinical or environmental. Furthermore, both smooth and rough phenotype strains exhibited high endotoxic activity, indicating that the O antigen component of LPS is not important for toxicity. 56 This is not unexpected as it is the lipid A moiety of LPS that generally induces toxic responses.
Inflammatory response induced by Bcc LPS
Bcc LPS is able to stimulate human neutrophils to better fight bacterial infection. LPS extracted from various Bcc strains was able to induce increased expression of CD11b on the surface of neutrophils. 57 CD11b is part of a cell signaling complex that stimulates the phagocytosis of infecting bacteria. It was also demonstrated that Bcc LPS could prime neutrophils for respiratory burst responses. Neutrophil stimulating effects were induced by all Bcc LPSs tested, independent of genomovar or source. 57 These activities may allow Bcc LPS to damage infected tissue by stimulating the release of reactive oxygen species and enzymes from activated neutrophils.
LPS from Gram-negative bacteria induces the production of pro-inflammatory cytokines in eukaryotic cells. Tumor necrosis factor (TNF) and interleukin-6 (IL-6) are released by various eukaryotic cells in response to Bcc LPS. More specifically, this effect has been demonstrated with whole human blood cells, a human macrophage cell line and isolated macrophages from mice. Again, there is no correlation between release of these cytokines and genomovar or source. 56, [58] [59] [60] Additionally, Bcc LPS can induce IL-8 production in whole human blood cells, as demonstrated in two separate studies. 59, 61 Thus, Bcc LPS can increase production of the pro-inflammatory cytokines TNF, IL-6, and IL-8 in human blood cells.
Shimomura et al. 58 analyzed three different preparations of Bcc LPS and studied the response of mouse macrophages to each. This group demonstrated that both a phenol-water LPS extraction described by Westphal et al. 62 and a further purification of this preparation could elicit an immune response in peritoneal macrophages from LPS-hyporesponsive mice, C3H/HeJ. These mice have a mutation in the Toll-like receptor 4 gene which recognizes and induces cellular responses to LPS. 63 In contrast, LPS purified using a procedure by Manthey et al. 64 designed to remove trace proteins resulted in a pure LPS preparation that no longer induced an immune response in C3H/HeJ mouse macrophages. 58 TNF-a and IL-6 production were induced by the pure LPS preparation in peritoneal macrophages isolated from the LPS-responsive mouse, C3H/HeN. IL-1b production was increased by the first two LPS preparations but only weakly induced by the pure LPS preparation. 58 This indicates that trace contaminants found in the first two LPS preparations, and not LPS itself, may be responsible for the observed increase in IL-1b production.
Observed pro-inflammatory responses are generally dependent upon the lipid A moiety of LPS. A deep rough mutant of Bcc strain ATCC 25416 lacking most of the core oligosaccharide, was still able to induce as much TNF production in human macrophages as complete LPS from the wild-type strain when differences in molecular weight were taken into account. 65 This provides further evidence of the importance of lipid A in induction of pro-inflammatory responses in eukaryotic cells.
Bcc LPS and antibiotic resistance
The structure and composition of Bcc LPS likely plays a role in the resistance of Bcc to many antibiotics. Spontaneous Bcc mutants that were resistant to trimethoprim/sulphamethoxazol (T/S) or chloramphenicol (Cam) had detectable changes in their LPS as observed by silver staining LPS preparations separated on polyacrylamide gels. Strains resistant to T/S had variations in the small molecular weight bands while the Cam-resistant mutants appeared to lack the high molecular weight O-antigen. Heterogeneities in the outer membrane proteins of these spontaneous mutants were also detected. It has not yet been determined whether the observed antibiotic resistance is due to changes in the LPS or in the outer membrane protein profile. 66 The resistance of Bcc to the membrane permeablization effects of polymyxin is due, at least in part, to LPS. Dansyl-polymyxin did not bind to whole cells of Bcc strains ATCC 25602 or to the clinical isolates K61-3 and PC715J, but it did bind to P. aeruginosa whole cells. LPS purified from these bacteria could bind dansyl-polymyxin with similar saturation kinetics. However, when equal amounts of LPS were used, Bcc LPS bound less than half the amount of dansylpolymyxin as P. aeruginosa LPS. 67 The LPS of Bcc potentially plays a role in the resistance of these bacteria to the effects of cationic antibiotics. The core oligosaccharide of Bcc LPS does not contain as much phosphate or 3-deoxy-D-manno-oct-2-ulosonic acid (Kdo) as core oligosaccharides of other Gram-negative bacteria. 56, 68, 69 Additionally, there are 4amino-4-deoxyarabinose (Ara4N) residues attached to the phosphate residues of the lipid A backbone. 68 In other bacteria, the addition of Ara4N to lipid A contributes to polymyxin resistance. [70] [71] [72] This modification likely neutralizes the anionic charge of the cell surface, thus inhibiting the binding and subsequent antibiotic effects of cationic compounds.
Protegrin-1 (PG-1) is a bactericidal 2 kDa cationic octadecapeptide that can act on a wide variety of bacteria. Albrecht et al. 73 hypothesized that the relative sensitivity or resistance to PG-1 correlates with the ability of the peptide to bind to LPS or lipid A. Various Bcc strains, including three CF isolates and two laboratory strains, were more resistant to killing by PG-1 than P. aeruginosa strains. Additionally, more radiolabled PG-1 bound to P. aeruginosa whole cells than to Bcc whole cells. Surface plasmon resonance was used to detect binding of PG-1 to purified LPS and lipid A. Less PG-1 bound to LPS and lipid A isolated from Bcc than to P. aeruginosa LPS or lipid A. 73 The observed reduced binding is likely due to the more neutral charge of Bcc LPS compared to P. aeruginosa LPS.
STRUCTURAL ASPECTS OF Bcc LIPID A
The fatty acid profiles of several Bcc strains have been determined. ETC, which is composed of LPS, carbohydrate, and protein, was isolated from Bcc strain 61g and the fatty acid content determined. This ETC contained mostly 3-hydroxytetradecanoic acid (3-OH-14:0) and hexadecanoic acid (16:0) or derivatives of these fatty acids. 52 Analysis of purified LPS from ATCC 25416, the Bcc genomovar I type strain, included these same fatty acids, 3-OH-14:0 and 16:0, as well as tetradecanoic acid (14:0) and 3-hydroxyhexadecanoic acid (3-OH-16:0). 65 Fatty acid profiles of Bcc LPS vary between different strains as demonstrated in a study by Galbraith et al. 74 All six Bcc strains analyzed contained 3-OH-14:0 with percentages ranging from 29% to 56% of the total fatty acids. The three B. vietnamiensis strains (Bcc genomovar V) had similar fatty acid compositions with 14:0 and 3-OH-16:0 being the major species in percentages of 19-24% and 37-39%, respectively. Bcc strain CIP 8236 (genomovar III) 75 also contained mostly 14:0 (20%) and 3-OH-16:0 (40%). However, two other genomovar III Bcc strains 75 had quite different LPS fatty acid profiles: Bcc strain CIP 8238 contained mostly dodecanoic acid (12:0) and 3-OH-16:0 while Bcc strain CDC 86 contained 16:0, 14:0, and 2-hydroxytetradecanoic acid (2-OH-14:0). 74 Thus, there appears to be no correlation between genomovar, particularly with genomovar III, and fatty acid profile. There is also no apparent correlation between lipid A composition and O-antigen as three strains with the same fatty acid profile, CIP 8236 and two B. vietnamiensis strains, all have different O-antigen structures ( Table 2 ). [76] [77] [78] The structure of the lipid A backbone from two different Bcc strains, ATCC 17759 (NCTC 10661) and ATCC 25416, are virtually identical to one another. Both strains have a typical phosphorylated GlcN disaccharide, but unlike other lipid A backbones, one or two Ara4N residues are attached to the phosphate groups ( Fig. 1) . At least one Ara4N residue was present in strain ATCC 17759, while ATCC 26416 had two Ara4N residues linked by a phosphodiester bond to the GlcN. 65, 68 Ara4N contains a positively charged ammonium group, and thus reduces the negative charge of the lipid A backbone induced by the phosphate groups. As mentioned previously, the presence a Serotypes O1-O7 were developed by Heidt et al. 96 with O8 and O9 described by Wernberg et al. 97 Serotypes A-J were described by Nakamura et al. 98 with K and L described by Soldatkina et al. 89 Serotype letters with '-McKevitt' were described by McKevitt et al. 99 Serotypes in parentheses were determined by Soldatkina et al. 89 after the structure of that particular strain had been determined. b Strains were used to develop type-specific antisera unless otherwise indicated by being encased in parentheses. In brackets {} is the genomovar of that particular strain, if known. 75 of Ara4N likely contributes to the resistance of Bcc to cationic antibiotics.
COMPOSITION OF Bcc CORE OLIGOSACCHARIDE
Initially, it was thought that Bcc LPS did not contain Kdo, a typical component of the core oligosaccharide. Studies using colorimetric assays to detect Kdo were unable to do so, or found that few strains had only a small amount of Kdo. 52, 69, 101 Later, it was determined that all Bcc strains do express Kdo, but it could only be detected by colorimetric assays after being released from the LPS by strong acid hydrolysis. 55 Despite the now confirmed presence of Kdo, there is about 5 times less Kdo in Bcc LPS than in P. aeruginosa LPS. 56, 68 Structural analysis of the LPS from ATCC 25416 revealed an unusual trisaccharide in the LPS core. In addition to the typical Kdo residue linked to the lipid A backbone, D-glycero-a-D-talo-oct-2-ulopyranosylonic acid (Ko) was detected. 100 This sugar is unusual, being found in few other bacteria such as Acinetobacter spp. or Yersinia pestis. [102] [103] [104] An Ara4N residue is attached to the Ko of the Kdo-Ko disaccharide. Additionally, Ara4N could replace the Ko in a non-stoichiometric manner. Thus the structure of the inner core oligosaccharide of Bcc is [b-L-Arap4N-(1® 8)-a-Kop-(2® 4)-Kdo] (Fig. 1 ). 100 The inability to release Kdo from Bcc LPS using mild acid hydrolysis is likely due to the Kdo-Ko moiety of the inner core.
This same Bcc strain, ATCC 25416, had the heptosyltransferase gene waaC insertionally inactivated resulting in a deep rough mutant lacking most of the core oligosaccharide. 65 This is in contrast with P. aeruginosa where the waaC gene appears to be essential. 105 The truncated LPS of the Bcc waaC mutant strain con-tained the lipid A backbone with the trisaccharide Ara4N-Ko-Kdo attached. 65 Thus, this study confirmed the previously determined structure of the inner core of Bcc strain ATCC 25416 and indicated that the trisaccharide is present on the lipid A before addition of the first heptose residue of the core oligosaccharide.
As both Bcc and P. aeruginosa are pathogens in CF patients, many studies of the core oligosaccharide have drawn comparisons the between the two bacteria. Both Bcc and P. aeruginosa contain rhamnose and glucose as the major components of the core oligosaccharide. 69, 100 But there is less phosphorus and more heptose in Bcc LPS than is typically found in P. aeruginosa LPS. 68, 69 Nelson et al. 106 noted that a monoclonal antibody directed to the P. aeruginosa core oligosaccharide was unable to cross react with Bcc LPS. Additionally, LPS of P. aeruginosa strain PAC608, a phenotypically rough strain, could not deplete human serum of anti-Bcc LPS antibodies. 107 Thus, the core oligosaccharide of Bcc and P. aeruginosa are compositionally and antigenically diverse.
There also appears to be some antigenic variability in the core structures of different Bcc strains. An immune response can be generated to the core oligosaccharide of Bcc strains in rabbits and in CF patients. Antisera from rabbits immunized with Bcc strain C1359, which is phenotypically rough, reacted with the core oligosaccharide of this strain and not with other Bcc strains tested. 56 Likewise, serum from a CF patient infected with one Bcc strain was unable to recognize LPS of other Bcc strains. 107 Rabbit antiserum to J2315, a genomovar III strain that lacks O-antigen, was used to immunoblot LPS extracted from Bcc strains of various genomovars. The anti-J2315 serum could react with LPS from all genomovar II (B. multivorans) strains tested and with some genomovar I and genomovar IV (B. stabilis) strains. However, the anti-J2315 serum did not react with LPS from most other genomovar III strains, which also lacked O-antigen. 108 This lack of cross-reactivity could be due to variations in core oligosaccharide structure or composition. Alternatively, the non-reactive genomovar III strains may have a defective or incomplete core oligosaccharide which lack the structural features necessary for antibody reactivity.
THE O-ANTIGEN MOIETY OF Bcc LPS
Many Bcc isolates from CF patients have a smooth phenotype, 109 but others, including some of the ET12 lineage involved in an epidemic in the CF community, lack the O-antigen portion of LPS. 108 Bcc strains that express O-antigen are more likely to be resistant to the killing effects of human serum than rough 206 Vinion-Dubiel, Goldberg strains. 110 But both smooth and rough strains can cause 'cepacia syndrome', which is characterized by the presence of viable bacteria in the blood. 45 Therefore, the inability to express O-antigen and thus be serum sensitive does not appear to affect the severity of a Bcc infection.
As the O-antigen is the most prominent and immunogenic component of the bacterial cell surface, the structure and composition of the O-antigen can be used as the basis of a serotype. Only one study has attempted to determine a relationship between Bcc infection in humans and serotype. Rabkin et al. 111 isolated Bcc from patients with hospital-acquired infections and the environmental source of these infections. The serotype of the strains was determined, but no apparent correlation between the serotype and the source or clinical outcome was observed. 111 Recently, the genomovar status of the strains used in the study of Rabkin et al. 111 was determined. Strains from multiple genomovars had the same serotype indicating that genomovar and serotype do not correlate. 112 There is an obvious need to develop vaccines to prevent Bcc infections in susceptible people, such as those living with CF. As the O-antigen is a strong immunogenic molecule, it may be a potential vaccine candidate for Bcc, as has been proposed for other Gram-negative bacteria, including P. aeruginosa. 113 However, as there does not appear to be a correlation between serotype and disease state, any O-antigen-based vaccine would need to be multivalent. On the other hand, Bcc is being developed for release into the environment for bioremediation or agricultural uses. If there is concern that the commercially useful Bcc strains may induce disease in susceptible hosts, a vaccine directed to the O antigen of these strains could be developed and given to high-risk patients.
Bcc serotypes and cross-reactivity
The first serotyping scheme for Bcc was developed by Heidt et al. in 1983. 96 By analyzing reactivity of immune sera with 282 Bcc strains, most of which were isolated from hospitals in France, seven different serotypes, O1-O7, were identified. 96 Six years later, two more serotypes were developed, O8 and O9, which were derived from Bcc strains isolated from American patients. 97 Another typing scheme was developed by Nakamura et al. 98 using Bcc strains isolated primarily in Japan. Ten specific antisera were developed, anti-A to anti-J. This study revealed some geographical bias in the serotypes of Bcc isolates with serotypes C, D, E, and F being found primarily in Japan. As the first seven serotypes identified by Heidt et al. 96 had been previously described, Nakamura et al. 98 compared the two serotyping schemes. Five of the antisera from each scheme could react with the same Bcc strains, thus indicating that the following antisera were equivalent: A-O7, C-O4, D-O1, G-O2, and I-O3. 98 Soldatkina et al. 89 used the antisera developed by the Heidt and Nakamura serotyping schemes to study the reactivity of these antisera with various Bcc strains. Cross reactivity of the antisera from the two schemes as described by Nakamura et al. 98 was confirmed. However, some of the strains analyzed could not be typed with these antisera. Therefore, two more serotypes, designated K and L, were identified. 89 This brings the total number of Bcc antisera to 16. McKevitt et al. 99 developed a Bcc-serotyping scheme using Bcc clinical isolates from three different locations in North America. Five different serotypes, A-E, were identified, one of which, serotype B, was derived from a strain lacking O-antigen. The reactivity of the McKevitt antisera to the Bcc type strains used to develop the Heidt serotyping scheme was determined. Bcc type strains O2 and O5 agglutinated with antisera E developed by McKevitt; O4 and O6 with A; and O1 with C. Additionally, two type strains used to develop the serotyping scheme of Nakamura et al. 98 agglutinated with antisera D of the McKevitt scheme. Several strains analyzed in this study could not be serotyped with the five antisera developed, thus, admittedly, this serotyping scheme is incomplete. 99 
Structure and composition of Bcc O antigen subunits
As the immunodominant O-antigen on the bacterial cell surface is the basis for a serotype, one can generally correlate the serotype with the O-antigen structure. The Oantigen structures of several Bcc strains from which antisera have been derived have been determined ( Table  2) . Different methods to determine the composition and structure of the O-antigens have been utilized including chemical degradation, [ 1 H]-and [ 13 C]-NMR spectroscopy, and mass spectroscopy. 76, 79, 82, 95 As mentioned previously, some Bcc strains agglutinate with more than one sera from different serotyping schemes and several of these strains also have the same O-antigen structure. Antiserum C of the Nakamura scheme and antiserum O4 of the Heidt scheme react with the same bacteria. 98 Likewise, the O antigen structures of type strain C (IMV 4209) and O4 (CIP 8238) are the same. 80, 83 However, this is not always the case as the Nakamura type I strain and the Heidt type O3 strain do not have the same O-antigen structure, [80] [81] [82] but the antisera derived from these strains cross react. 98 Additionally, O2 antisera from the Heidt serotyping scheme and G antisera of the Nakamura serotyping scheme react with Bcc strains, IMV 4137 and IMV 598/2. 89 However, the determined O-antigen structures of these two strains [® 2)-a-L-Rhap-(1® 4)-a-D-Galp-(1® ] 86, 93 is not similar to the O-antigen structure of the O2 serotype strain, CIP 8236, which is 76 Thus, the reactivity of a particular Bcc strain to antisera does not always correlate with the structure of the O-antigen.
When studying the O-antigen subunit structures from Bcc, there are three things to notice. First, many of the O-antigen subunits are simple structures, having only two or three sugar residues per subunit. Those subunits with three sugars have at least one sugar residue repeated; for example, the O antigen subunit of the serotype K strain, IMV 3181, is a polyrhamnose. 90 Second, there are some unusual sugar residues found in the O antigen structures from Bcc. For example, LD-heptose is usually found only in the core oligosaccharide of other Gram-negative bacteria, and the D forms of rhamnose and fucose are found in O-antigen subunits of Bcc and other bacteria of the Pseudomonadaceae family as opposed to the L forms of these sugars. 80, 88, 91 Third, there are two Oantigen subunit structures of Bcc that are in common with P. aeruginosa O-antigen subunits: the O-antigen subunits of Bcc serotype O3 and O5 are identical to the O-antigen subunits of P. aeruginosa serogroup O15 and O17, respectively. 81 208 Vinion-Dubiel, Goldberg 
Bcc O-antigen genetic loci
The genome sequence of the Bcc strain J2315 is currently being annotated, but the raw sequence information is available on the Sanger Institute website <http://www.sanger.ac.uk/Projects/B_cepacia/>. The genetic locus responsible for biosynthesis of O-antigen has been located in this sequence, despite the fact that J2315 lacks O-antigen. 108 Additionally, the Oantigen locus from Bcc strain PC222, a genomovar IV (B. stabilis) strain expressing serotype O5 O antigen, has been sequenced and characterized (Fig. 2) . 114 The putative genes in the O-antigen loci from Bcc strains J2315 and PC222 have been identified based on homology to known polysaccharide biosynthetic genes in GenBank <http://www.ncbi.nlm.nih.gov/>. Both of these O-antigen loci contain the four putative genes responsible for biosynthesis of the sugar rhamnose, rmlBACD. These loci also have two putative genes, wzm and wzt, that encode for a complete ATP binding cassette 'ABC' transporter. The ABC transporter-dependent pathway is generally used by bacteria to transport simple O-antigen subunits, like homopolysaccharides or disaccharides, 115 which is descriptive of Bcc O-antigens. The O-antigen locus of Bcc strain PC222 also contains a putative gene encoding for UDP-N-acetyl-glucosamine (UDP-GlcNAc) 2-epimerase. This putative enzyme converts UDP-GlcNAc to UDP-N-acetyl-mannosamine (ManNAc), which is found in the O antigen subunit of Bcc serotype O5 strains ( Table 2) . A glycosyltransferase homologue is also present in the O-antigen locus of PC222. Thus, the first eight genes of the O antigen locus in Bcc strain PC222 appear to be sufficient, theoretically, for biosynthesis of the serotype O5 O-antigen ( Fig. 3 ).
Following the first eight genes in PC222 and their homologues in J2315, there is a divergence in the two sequences. J2315 contains multiple open reading frames, including a putative transposase, while PC222
has one large open reading frame (ORF) and one small ORF with little homology to any known sequences. Following this divergent region n both sequences there are four putative genes similar to those found in the O antigen loci from B. mallei and B. pseudomallei: wbiF, wbiG, wbiH, and wbiI. 117, 118 It is unknown if these putative genes play a role in O-antigen biosynthesis in Bcc. However, the wbiI homologue, which is a member of a bifunctional dehydratase/reductase family of genes involved in polysaccharide biosynthesis, is conserved among all Bcc strains tested, including the nine serotype strains from the Heidt and Werneburg serotyping scheme ( Fig. 4 ). 75 
OTHER EXTRACELLULAR POLYSACCHARIDES OF Bcc
Many strains of Bcc have been noted to express acidic exopolysaccharides (EPS). When Bcc strains that produce a high amount of EPS are grown on solid media, a mucoid phenotype is observed. 119, 120 This phenotype is rare, but is found among both clinical and environmental isolates. 36 Three Bcc strains, one CF and two environmental isolates, have been shown to express an EPS with a short repeating subunit structure, PS-I (Fig. 5A) . 121, 122 Several other strains, including the three that produce PS-I, express a heptasaccharide EPS (PS-II), the structure of which is shown in Figure 5B . 119, 123, 124 While this same heptasaccharide structure has been determined to be produced by various Bcc strains in three separate studies, 119, 123, 124 another study noted that exopolysaccharide composition of various Bcc strains was Lipopolysaccharide of Burkholderia cepacia complex 209 [122] [123] [124] not consistent. 125 Thus, it may be possible that Bcc produce exopolysaccharides other than those previously reported.
In P. aeruginosa, the overproduction of the mucoid exopolysaccharide alginate, which is a non-repeating linear polymer of (1® 4)-linked b-D-mannuronic acid and a-L-guluronic acid, is virtually diagnostic of chronic lung infections in CF patients. Whether the mucoid phenotype of Bcc is also critical for maintenance of pulmonary infections in these patients is not known. However, a recent study using a mouse model of infection demonstrated that a Bcc isolate that could persistently colonize the mouse lung had a shinier colony morphology on solid media than the original infecting strain. Both the infecting and persistent strains produced EPS with the composition being identical to PS-II, but the persistent strain produced more EPS than the original strain. 126 This indicates that the overproduction of EPS may play a role in persistent Bcc pulmonary infection.
CONCLUSIONS
In summary, Bcc are potentially useful bacteria for bioremediation and increasing agricultural crop production but can cause potentially mortal infections in humans. Therefore, if this organism is to be developed for commercial uses, learning more about potential virulence factors in Bcc, like LPS, is essential. It is known that the lipid A component of LPS can induce severe immune responses in human cells. Additionally, the presence of Ara4N residues on the lipid A backbone and the Ko substitution in the core oligosaccharide of Bcc contribute to the neutralization of the usually anionic charge of the bacterial cell surface. This inhibits cationic antibiotics from binding to the cell surface thus making Bcc resistant to the effects of these antibiotics. The O-antigen does not appear to play a role in Bcc disease, but it may be possible to develop vaccines to the O-antigen of commercially useful Bcc, thus preventing human infection by these strains.
